CrowdStrike (NASDAQ:CRWD) Price Target Raised to $395.00
otakuyassine3@gmail.com CrowdStrike (NASDAQ:CRWD – Free Report) had its price objective hoisted by Wedbush from $390.00 to...
Wedbush
BioCryst Pharmaceuticals (NASDAQ:BCRX) Now Covered by Wedbush
Wedbush initiated coverage on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) in a...
Wedbush Predicts Douglas Emmett FY2026 Earnings
Douglas Emmett, Inc. (NYSE:DEI – Free Report) – Equities research analysts at Wedbush issued their...
Alphabet (NASDAQ:GOOG) Given Outperform Rating at Wedbush
Alphabet (NASDAQ:GOOG – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers...
Wedbush Lifts Earnings Estimates for Travere Therapeutics
Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) – Wedbush upped their FY2024 EPS estimates for...
Netflix’s (NFLX) “Outperform” Rating Reaffirmed at Wedbush
Netflix (NASDAQ:NFLX – Get Free Report)‘s stock had its “outperform” rating reiterated by stock analysts...
Blueprint Medicines’ (BPMC) Outperform Rating Reiterated at Wedbush
Wedbush reaffirmed their outperform rating on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in...
Texas Roadhouse (NASDAQ:TXRH) Given Outperform Rating at Wedbush
Wedbush reiterated their outperform rating on shares of Texas Roadhouse (NASDAQ:TXRH – Free Report) in...
Tripadvisor (NASDAQ:TRIP) Receives “Neutral” Rating from Wedbush
Wedbush reissued their neutral rating on shares of Tripadvisor (NASDAQ:TRIP – Free Report) in a...
Snowflake (NYSE:SNOW) Stock Rating Lowered by Wedbush
Snowflake (NYSE:SNOW – Get Free Report) was downgraded by analysts at Wedbush from a “strong-buy”...
Wedbush Reiterates “Outperform” Rating for IDEAYA Biosciences (NASDAQ:IDYA)
IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report)‘s stock had its “outperform” rating restated by equities...